dr waks on ongoing research in residual her2 breast cancer
Published 2 weeks ago • 63 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
0:59
dr waks on unmet needs in patients with her2 breast cancer
-
1:42
dr waks on anthracycline- vs taxane-based therapy in her2 breast cancer
-
1:33
dr. mccann on ongoing research in her2-positive breast cancer
-
1:20
dr tolaney on ongoing clinical trials in early-stage her2 breast cancer
-
2:32
dr waks on key questions regarding the first-line use of t-dxd in her2 breast cancer
-
20:25
her2 early-stage breast cancer: peri-operative therapy
-
7:11
case 1: adjuvant therapy for residual disease in her2 breast cancer
-
2:25
reducing risk in residual breast cancer
-
1:07:43
new & supporting data for optimizing therapy in her2 breast cancer | dr. mahtani & dr. schwartzberg
-
1:05:11
ask the expert: early-stage her2-positive breast cancer with adrienne waks, md
-
0:41
dr. o’sullivan on individualized her2-targeted therapy in her2 breast cancer
-
0:56
dr. hamilton on recent advances in her2 breast cancer
-
1:22
dr. borgen on successful progress in her2 breast cancer
-
2:03
dr. hurvitz on novel agents in her2-positive breast cancer
-
1:39
dr. hurvitz on the lack of predictive biomarkers in her2 breast cancer
-
0:50
dr. osborne on pertuzumab in her2 breast cancer
-
2:05
dr. geyer discusses challenges in her2-positive metastatic breast cancer management
-
1:52
dr. geyer discusses pertuzumab in her2 breast cancer
-
0:49
dr. o’regan on prognostic value of pcr in her2 breast cancer